Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-22T23:32:51.537Z Has data issue: false hasContentIssue false
  • English
  • Français

Vers un élargissement des indications des antidépresseurs

Published online by Cambridge University Press:  16 April 2020

H Allain ,
C Benéton  and
E Bellissant
H Allain
Affiliation:
Laboratoire de pharmacologie, faculté de médecine, avenue du Professeur-Léon-Bernard, 35043Rennes Cedex, France
C Benéton
Affiliation:
Laboratoire de pharmacologie, faculté de médecine, avenue du Professeur-Léon-Bernard, 35043Rennes Cedex, France
E Bellissant
Affiliation:
Laboratoire de pharmacologie, faculté de médecine, avenue du Professeur-Léon-Bernard, 35043Rennes Cedex, France
Get access

Résumé

Les données neurochimiques directes ou indirectes obtenues dans différentes affections du système nerveux central (SNC) constituent la base rationnelle de I'utilisation des médicaments dans des indications précises. Les antidépresseurs (AD) tricycliques agissant sur les principales amines du SNC trouvent ainsi des applications thérapeutiques variées en dehors de la dépression. L'arrivée de nouveaux AD au mécanisme d'action, soit plus cibé (la sérotonine), soit différent (IMAO) pose de nouveau cette question des indications psychiatriques et neurologiques, qui ne peut être résolue que par des essais méthodologiquement irréprochables. Une telle approche évitera d'ignorer pendant des années des effets thérapeutiques incontestables d'une molécule ancienne, tel que ce fut le cas de la clomipramine dans les troubles obsessifs-compulsifs.

Keywords

antidépresseursdépressionsérotonineindications thérapeutiques
Type
Research Article
Information
European Psychiatry , Volume 9 , Issue S2: Psychiatrie: quelles convergences pour quelle insertion? , 1994 , pp. 25 - 29
Copyright
Copyright © Elsevier, Paris 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Références

Allain, HBentue-Ferrer, DReymann, JMRMartinet, JPSystemès dopaminergiques et fonctions cognitives. Neuropsy 1990;4:17–22Google Scholar
Allain, HLieury, ABrunet-Bourgin, FMirabaud, CTrebon, PLecoz, FGandon, JMAntidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1992;106:S56–S61CrossRefGoogle ScholarPubMed
Arango, VUnderwood, MMann, JAlterations in monoamine receptors in the brain of suicide victims. J Clin Psychopharmacol 1992;12:(suppl2):8s–llsCrossRefGoogle ScholarPubMed
Austin, MPRoss, MMurray, CO’ Carroll, REEbmeler, KPGoodwin, GMCognitive function in major depression. J Affective Disord 1992;25:21–30CrossRefGoogle ScholarPubMed
Benkelfat, CMurphy, DIZohar, Jet al. Clomipramine in obsessivecompulsive disorder. Further evidence for serotonergic mechanism of action. Arch Gen Psychiatry 1989;46:23–8CrossRefGoogle Scholar
Bitran, DHull, EHomes, GHLookingland, KJRegulation of male rat copulatory behavior by preoptic incertohypothalamic dopamine neurons. Brain Res Bull 1988;20:323–31CrossRefGoogle ScholarPubMed
Bottiglieri, TGodfrey, PFlynn, TCarney, MWPToone, BKReynolds, EHCerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S adenosylmethionine. J Neurol Neurosurg Psychiatry 1990; 53:1096–8CrossRefGoogle ScholarPubMed
Carruba, MOMantegazza, PMomo, Met al. Peripheral and central mechanisms of action of serotoninergic anorectic drugs. Appetite 1986;7:105–13CrossRefGoogle ScholarPubMed
Chouinard, GAnnable, LFontaine, Ret al. Alprazolam in the treatment of generalized anxiety and panic disorders: a double blind, placebo-controlled study. Psychopharmacology 1982;77:229–33CrossRefGoogle Scholar
Cook, EAutism: review of neurochemical investigation. Synapse 1990; 6:282–308CrossRefGoogle ScholarPubMed
Cooper, SDourish, CBarber, DFluoxetine reduces food intake by a cholecystokinin - independent mechanism. Pharmacol Biochem Behav 1990;35:51–4CrossRefGoogle ScholarPubMed
Delini-Stula, APerspectives in the development of antidepressant drugs. Int Psychiatry 1991;7:120–5Google Scholar
Delumeau, JCBentue-Ferrer, DGandon, JMAmrein, RBureau, MAllain, HMonoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. J Neural Transm 1994;41:259–66Google ScholarPubMed
Diehl, DGershon, SThe role of dopamine in mood disorders. Compr Psychiatry 1992;33:115–20CrossRefGoogle ScholarPubMed
Donders, SHPieters, GFHeevel, JGRoss, HASmals, AGet al. Disparity of thyrotropin (TSH) and prolactine responses to TSH-releasing hormone in obesity. J Clin Endocrinol & Metab 1985; 61:56–9CrossRefGoogle Scholar
Enas, GGPope, HGVevine, LRFluoxetine in bulimia nervosa: double blind study. New Research Program and Abstracts. American Psychiatric Association 142nd Annual Meeting 1989; p 204Google Scholar
Feinmann, CPain relief by antidepressants: possible modes of action. Pain 1985;23:1–8CrossRefGoogle ScholarPubMed
Ferguson, JMFeighner, JPFluoxetine-induced weight loss in over-weight non-depressed humans. Int J Obesity 1987;11:163–70Google ScholarPubMed
Fibiger, HCPhillips, AGRole of catecholamine transmitters in brain reward systems: implications for the neurobiology of affectIn: Engel, JOreland, L eds. Brain Reward Systems and Abuse New York: Raven Press, 61–74Google Scholar
Fields, HHeinricher, MMason, PNeurotransmitters in nociceptive modulatory circuits. Ann Rev Neurosci 1991;14:219–45CrossRefGoogle ScholarPubMed
Goodman, WKPrice, LHRasmussen, ADelgadop, LMeninger, GRChamey, DSEfficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 1989;46:36–44CrossRefGoogle ScholarPubMed
Gringras, MAA clinical trial of Tofranil in rheumatic pain in general practice. J Int Med Res 1976;4(suppl 2):41–9Google ScholarPubMed
Gwirtsman, EEGuze, BHYager, JGainsley, BFluoxetine treatment of anorexia nervosa: an open clinical trial. J Psychiatry 1990; 51:378–82Google Scholar
Hantouche, EBaddoura, CHypothèses biologiques dans le trouble obsessionnel-compulsif. Encéphale 1990;16:241–9Google Scholar
Hull, EBazzett, TJWarner, RKEaton, RCThompson, JTDopamine receptors in the ventral tegmental area modulate male sexual behavior in rats. Brain Res 1990;512:1–6CrossRefGoogle ScholarPubMed
Jenike, MABaer, LSummergrad, PMinichiello, WEHolland, ASeymour, RSertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry 1989; 147:923–8Google Scholar
Jimerson, DCLeseim, MDKaye, WHet al. Serotonin and symptom severity in eating disorders. Biol Psychiatry 1989;25:143ACrossRefGoogle Scholar
Johnston, DGTroyer, IEWhitset, IClomipramine treatment of agoraphobic women. Arch Gen Psychiatry 1988;45:453–9CrossRefGoogle ScholarPubMed
Kapur, SMann, JRole of the dopaminergic system in depression. Biol Psychiatry 1992;32:1–17CrossRefGoogle ScholarPubMed
Kelly, DGuirguis, WFrommer, EMitchell-Heggs, NSargant, WTreatment of phobic states with antidepressants: a retrospective study of 246 patients. Br J Psychiatry 1970;116:387–98CrossRefGoogle ScholarPubMed
Kitamura, YZhao, XHTakei, MYonemitsu, ONomura, YEffects of antidepressants on the glutamatergic system in mouse brain. Neurochem Int 1991;19:247–53CrossRefGoogle Scholar
Klein, DFDelineation of two drug-responsive anxiety syndromes. Psychopharmacologia (Berlin) 1964;5:397–408CrossRefGoogle ScholarPubMed
Kramer, MVogel, WDijohnson, Cet al. Antidepressants in depressed schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry 1989;46:922–8CrossRefGoogle ScholarPubMed
Leibowitz, MRQuitkin, FMStewart, JWMcGrath, PJHarrisson, WMMarkowitz, JSet al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129–37CrossRefGoogle Scholar
Luttrell, LOstrowski, JCotecchia, SKendall, HLefkowitz, RAntagonism of catecholamine receptor signaling by expression of cytoplasmic domains of the receptor. Science 1993;259:1453–7CrossRefGoogle Scholar
Magni, GThe use of antidepressants in the treatment of chronic pain. A review of the current evidence. Drugs 1991;42:730–48CrossRefGoogle ScholarPubMed
Manji, HKG proteins: implications for psychiatry. Am J Psychiatry 1992;149:746–60Google Scholar
Mas, MGonzalez-Mora, JLouilot, ASole, CGuadalupe, TIncreased dopamine release in the nucleus accumbens of copulating male rats as evidenced by in vivo voltammetry. Neurosci Lett 1990; 110:303–8CrossRefGoogle ScholarPubMed
Mcintosh, TKBarfield, RJBrain monoaminergic control of male reproductive behavior. II Dopamine and the post ejaculatory refractory period. Behav Brain Res 1984;12:267–73CrossRefGoogle ScholarPubMed
Montgomery, SASuicide and antidepressants. Drugs 1992;43(suppl 2): 24–31CrossRefGoogle ScholarPubMed
Moreau, JLJenck, PMartin, JRMortas, PHaefely, WEAntidepressant treatment prevents chronic impredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 1992;2:43–9CrossRefGoogle Scholar
Murphy, JMWaller, MBGatto, CJet al. Effects of fluoxetine on the intragastric self administration of ethanol in the alcohol preferring P line of rats. Alcohol 1988;5:283–6CrossRefGoogle ScholarPubMed
Naranjo, CASellers, EMSullivanji, Tet al. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987;41:266–74CrossRefGoogle ScholarPubMed
Norden, MJFluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:885–93CrossRefGoogle ScholarPubMed
Ollat, HBousser, MGPhysiopathogénie de la migraine. Ann Med Interne 1992;143:173–93Google Scholar
Potter, WRudorfer, MManji, HThe pharmacological treatment of depression. N Engl J Med 1991 ;325:633–42Google ScholarPubMed
Prasad, AEfficacy of trazodone as an anti-obsessional agent. Neuropsychobiology 1986;15:19–21CrossRefGoogle ScholarPubMed
Schmidt, HSClark, RWHyman, PRProtriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977;134:183–5Google ScholarPubMed
Shyu, KWLin, MTWu, TCPossible role of central serotoninergic neurons in the development of dental pain and aspirin induced analgesia in the monkey. Exp Neurol 1984;84:179–87CrossRefGoogle ScholarPubMed
Siris, SVan Kammen, DDocherty, JUse of antidepressant drugs in schizophrenia. Arch Gen Psychiatry 1978;35:1368–77CrossRefGoogle Scholar
Taub, ARelief of post-herpetic neuralgia with psychotropic drugs. J Neurosurg 1973;39:235–9CrossRefGoogle ScholarPubMed
Thierry, AMTassin, JPBlanc, GGlowinski, JSelective activation of the mesocortical dopamine system by stress. Nature 1976; 263:242–4CrossRefGoogle ScholarPubMed
Westenberg, HJMDen-Boer, JAClinical and biochemical effects of selective serotonin-uptake inhibitors in anxiety disordersIn: Gastpur, MWakelin, JS eds. Selective 5HT Reuptake Inhibitors Novel or Common Place Agents? Basel: Karger, 1988;84–99Google Scholar
Willner, PDepression: a Psychobiological Synthesis New York: Wiley, 1985Google Scholar
Zohar, JInsel, TRObsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987;22:667–87CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.